Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

The Hydroponics Company’s shares surge after signing medicinal cannabis deal

Initial products imported to Australia will include cannabidiol oil.
cannabis cultivation
Recently granted a medicinal cannabis licence

The Hydroponics Company Ltd’s (ASX:THC) subsidiary, Canndeo Ltd, has signed a distribution agreement with Endoca B.V. to distribute medicinal cannabis products into Australia.

Endoca is one of Europe’s most highly respected suppliers of GMP (Good Manufacturing Practice) certified medicinal cannabis, with sales exceeding €50 million per annum.

Initial products imported to Australia will include CBD (cannabidiol) oil, CBD capsules and a unique CBD + CBDA (cannabidiolic acid) oil.

The Hydroponics Company’s shares were last trading 59% higher intra-day, at $0.835.

Focus on rapid commercialisation

Canndeo Ltd was recently granted a medicinal cannabis licence by the Office of Drug Control, Australia that authorises the cultivation and growth of cannabis plants for medicinal purposes.

READ NEXT: The Hydroponics Company granted Medicinal Cannabis Licence

Obtaining the licence meets one of Canndeo’s key milestones on the path to its goal – the commercial cultivation of medicinal cannabis in Australia.

This is the second of three licences approved, with the company having lodged a manufacturing licence and is awaiting approval.

Significant step forward in distributing high quality medicinal cannabis

The agreement with Endoca provides a solid platform to expand the company’s activities including its focus on rapid commercialisation.

It is a significant step forward in distributing high quality medicinal cannabis products through European pioneers in extraction and purification.

David Radford, chief executive officer, commented: “The distribution agreement with Endoca is an important milestone for THC and Canndeo in its program to deliver medicinal cannabis solutions into Australia.

“We are very pleased that Endoca recognises Canndeo as the right partner for distributing medicinal cannabis solutions and we look forward to developing this relationship as more Australian doctors and patients seek a positive way forward with medicinal cannabis.”

View full THC profile View Profile

The Hydroponics Company Ltd Timeline

Related Articles

e-Therapeutics
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms
test tubes filled with blood
November 02 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use